American Society of Hirudotherapy

Supraclavicular flap repair in the free flap era

Research article published in ANZ journal of surgery (2018)

Last Updated: November 1, 2026ASH Editorial · based on the books
Research article — evidence review: Off-label use means application outside the FDA-cleared indication. Clinical evidence (RCTs or systematic reviews) supports this use, but the FDA has not cleared it.Article reference: Content describes science, methodology, or organizational reference material — not a clinical efficacy claim.
Evidence: Narrative reviewClinical LiteratureTrautman et al. · ANZ journal of surgery, 2018

Abstract

BACKGROUND: Supraclavicular flap (SCF) repair is widely reported in head and neck surgery in select patients and defects. The authors' objective is to present our series of 30 patients who underwent SCF repair for varying defects and to review the scope and outcome of SCF repair in the literature. METHODS: The authors contributed primary evidence of 30 cases of SCF repair. Our outcomes are compared with those reported in the last 5 years' literature; 33 articles published between January 2012 and January 2017 that present original clinical experience of 528 SCFs. RESULTS: SCF is suitable for a wide variety of oral cavity, pharyngeal, skull base and cutaneous defects. Consistent with our experience, SCF is highly reliable even in previously irradiated or dissected necks, so long as the supraclavicular artery is intact. Our case series shows minor complications in 3/30 (10%) and flap loss in 1/30 (3.3%) cases. The literature reports a similar rate of complete flap failure of 3.4% and a slightly higher average minor complication rate of 24.6%. CONCLUSION: We add our experience of 30 cases of SCF repair to the international literature. We experienced a complication rate lower than the reported average, and maintain that the SCF is an excellent reconstructive option in patients with previously irradiated necks or comorbidities that affect microvasculature and anaesthetic resilience.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleReview
Indexed MeSH termsAdultAgedAged, 80 and overEstheticsFemaleFree Tissue FlapsGraft RejectionHead and Neck NeoplasmsHumansMaleMiddle AgedNeck DissectionQuality of LifePlastic Surgery ProceduresRisk AssessmentShoulderSurgical FlapsWound Healing

Summary

In a 30-patient series of supraclavicular flap repairs, the authors report 10% minor complications and 3.3% flap loss, compared with 3.4% complete failure and 24.6% minor complications across 528 SCFs from 33 recent publications.

Why This Matters for Hirudotherapy

This paper reports a single-team series of 30 supraclavicular flap (SCF) reconstructions alongside a review of 528 SCFs from the recent literature, finding the pedicled SCF highly reliable for head, neck, and oral-cavity defects, including in previously irradiated or dissected necks, with reported complete flap failure around 3 to 3.4% and minor complications of roughly 10% in their series versus about 24.6% in the literature. It is relevant to hirudotherapy because flap reconstruction is the broader clinical arena where venous congestion of a compromised flap can prompt adjunctive leech therapy; understanding when a robust pedicled option like the SCF is chosen helps frame where congestion-salvage tools are and are not needed. As a small case series combined with a literature review and no comparison group or any mention of leech use, it offers descriptive reliability data rather than controlled evidence.

Citation

Reference (Vancouver style)

Trautman J, Gore S, Potter M, Clark J, Hyam D, Tan NC, et al. Supraclavicular flap repair in the free flap era. ANZ J Surg. 2018;88(6):540-546. doi:10.1111/ans.14263. PMID: 29148237

Bibliographic details (authors, volume, pages, DOI) are taken from the PubMed record.

Added to ASH library: May 28, 2026 · Site last updated: November 1, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.